Sihuan Pharmaceutical (HKG:0460) non-wholly owned subsidiaries Huisheng Biopharmaceutical and Meiyan Space signed an exclusive authorization cooperation deal for Huisheng's semaglutide injection.
Meiyan Space, Sihuan's medical aesthetics unit, will have exclusive engagement rights in mainland China for the weight loss drug, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments